NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical TrialWASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio’s ANVS-25002 open-label Parkinson’s disease clinical trial. NeuroRPM’s platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson’s motor symptoms.
NeuroRPM Inc. Announces FDA Clearance for NeuroRPM, the AI-Powered Remote Monitoring App for Parkinson’s Disease on Apple Watch
NeuroRPM Inc., a digital health company, has received FDA clearance for NeuroRPM, a breakthrough product that uses AI and Apple Watch to continuously and passively monitor bradykinesia, tremor, and dyskinesia, the cardinal symptoms of Parkinson's disease. The product includes the most advanced and comprehensive monitoring capabilities for Parkinson’s disease available on a wearable device, allowing for day-to-day tracking of the full range of disease symptoms.
